反应详情

Tert-butyl (1-(4-(1-((1H-imidazol-2-yl)methyl)-2-oxo-7-phenyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-6-yl)phenyl)cyclobutyl)carbamate (5 mg, 0.001 mmol) was dissolved in TFA (1 ml). The resulting mixture was stirred for 30 seconds at room temperature and evaporated under reduced pressure. The deprotected compound was taken back twice into diethyl ether and the solid formed was washed twice with DCM. The remaining solvent was removed under reduced pressure and dried to afford the title compound (5 mg, quantitative). LCMS (Method A): RT=2.80 min, M-NH2=435. 1H NMR (500 MHz, MeOD): 7.44 (1H, s), 7.41 (2H, s), 7.31-7.26 (4H,m), 7.18-7.16 (3H,m), 7.06-7.05 (2H, m), 5.44 (2H, s), 4.97 (2H, s), 2.66-2.60 (2H, m), 2.49-2.43 (2H, m), 2.14-2.10 (1H, m), 1.89-1.82 (1H, m).

1. customevaporated under reduced pressure
2. customthe solid formed
3. washwas washed twice with DCM
4. customThe remaining solvent was removed under reduced pressure
5. customdried